These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32789089)

  • 1. Pulmonary Embolism in Acquired Hemophilia A: A Rare Complication With Factor VIII Inhibitor Bypassing Activity Therapy.
    Aslam HM; Chong T; Park J; Nicolosi T; Shah R
    Cureus; 2020 Jul; 12(7):e9152. PubMed ID: 32789089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur.
    Miatech JL; Kantamani D; Stagg MP
    Cureus; 2021 Oct; 13(10):e19145. PubMed ID: 34868780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
    Ettingshausen CE; Hermans C; Holme PA; Cid AR; Khair K; Oldenburg J; Négrier C; Botha J; Lelli A; Windyga J
    Ther Adv Hematol; 2023; 14():20406207231184323. PubMed ID: 37529276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic COVID-19-Associated Acquired Hemophilia A and Disseminated Intravascular Coagulation From a Bypassing Agent.
    Attah A; Huffman D; Asawa P; Edlukudige Keshava V; Shah D
    J Med Cases; 2024 Jun; 15(6):106-109. PubMed ID: 38855293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism.
    Wool GD; Chapel D; Treml A; Miller JL
    Transfusion; 2017 Jul; 57(7):1827-1832. PubMed ID: 28436106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undiagnosed Acquired Hemophilia A: Presenting as Recurrent Gastrointestinal Bleeding.
    Roy AM; Siddiqui A; Venkata A
    Cureus; 2020 Sep; 12(9):e10188. PubMed ID: 33029467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
    J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
    Aledort LM
    Haemophilia; 2008 Jan; 14(1):39-43. PubMed ID: 17961169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H; Ewenstein B
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post splenectomy fatal pulmonary embolism in a patient with moderate hemophilia a.
    Davoodabadi A; Adib MM; Keleidari B
    Iran J Med Sci; 2011 Jun; 36(2):136-40. PubMed ID: 23358445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus.
    Khodamoradi Z; Nazarinia MA; Bazdar S
    Curr Rheumatol Rev; 2017; 13(3):236-238. PubMed ID: 28523993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of congenital and acquired hemophilia].
    Higasa S
    Rinsho Ketsueki; 2017; 58(7):857-865. PubMed ID: 28781285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy.
    Htet NN; Barounis D; Knight C; Umunna BP; Hormese M; Lovell E
    Am J Emerg Med; 2020 Mar; 38(3):539-544. PubMed ID: 31176578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis.
    Yin EB; Tan B; Nguyen T; Salazar M; Putney K; Gupta P; Suarez JI; Bershad EM
    Neurocrit Care; 2017 Aug; 27(1):51-59. PubMed ID: 28243997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.
    Sallah S
    Haemophilia; 2004 Mar; 10(2):169-73. PubMed ID: 14962206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two elderly patients with difficult-to-treat acquired hemophilia A].
    Saito M; Morioka M
    Nihon Ronen Igakkai Zasshi; 2016; 53(4):424-430. PubMed ID: 27885231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
    Livnat T; Martinowitz U; Zivelin A; Seligsohn U
    Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.